Last edition
News about "metastatic Castration-Resistant Prostate Cancer "
GI Innovation, Johnson & Johnson Partner for Phase Ib Trial in Advanced Prostate Cancer
GI Innovation enters clinical supply agreement with Johnson & Johnson to evaluate GI-102 and pasritamig combination therapy in metastatic castration-resistant prostate cancer patients.
Metastatic Castration-Resistant Prostate Cancer | 21/03/2026 | By News Bureau | 102
GSK Gains Exclusive Rights to Syndivia's Prostate Cancer ADC
GSK has obtained exclusive rights from Syndivia for a preclinical Antibody-Drug Conjugate (ADC) targeting metastatic Castration-Resistant Prostate Cancer (mCRPC), addressing an urgent need for novel therapies. The agreement expands GSK’s oncology pipeline with a potential best-in-class ADC designed to deliver enhanced anti-tumour activity.
Metastatic Castration-Resistant Prostate Cancer | 27/10/2025 | By Dineshwori | 291
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy